Clinical Scorecard: Molecular Subtyping and Immunotherapy in Fertility-Preserving Approaches for Endometrial Cancer: Challenges and Prospects

At a Glance

Key Highlights

• Endometrial cancer incidence is rising, with approximately 417,000 new cases in 2020.
• Fertility-sparing treatment (FST) is available for select patients to preserve fertility.
• Molecular subtypes significantly influence prognosis and treatment response.
• POLE mutations are associated with higher complete remission rates.
• Immune checkpoint inhibitors may enhance outcomes in fertility-sparing treatment.

Guideline-Based Recommendations

Diagnosis

• Use hysteroscopic resection for accurate pathological diagnosis.

Management

• First-line FST includes LNG-IUS; progestins like MPA and MA are alternatives.

Monitoring & Follow-up

• Patients must be informed of the need for total hysterectomy if FST fails.

Risks

• Patients with P53abn are not eligible for fertility-sparing therapy due to poor prognosis.

Patient & Prescribing Data

Women with well-differentiated endometrioid adenocarcinoma, grade 1, FIGO stage IA.

High-dose progestin regimens (160-320 mg for MA, 400-600 mg for MPA) yield superior outcomes.

Clinical Best Practices

• Ensure multidisciplinary team guidance for FST.
• Discuss risks of persistence or recurrence in patients with Lynch syndrome.

Related Resources & Content

• Global Cancer Statistics 2020
• NCCN Guidelines for Endometrial Cancer